Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

This study is testing an experimental drug called TYRA-430 in patients with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have specific changes in a growth signaling pathway called FGF/FGFR. Researchers want to see if the drug is safe and shows early signs of fighting the cancer. **You may be eligible if...** - You are 18 or older with good performance status (ECOG 0-1) - You have advanced, unresectable liver cancer or another advanced solid tumor with FGF/FGFR pathway changes confirmed by testing - You have already received standard-of-care treatments for your cancer - Your liver, kidney, and blood counts are within acceptable ranges - You are able to swallow oral medications **You may NOT be eligible if...** - Your liver cancer is at an early or intermediate stage still eligible for localized treatment - Your liver function is significantly impaired (Child-Pugh class B or C) - You have untreated brain metastases or other serious active conditions Talk to your doctor to see if this trial is right for you.